Nadia Fida, MD
Advanced Heart Failure and Transplant Cardiology · Baytown, TXNPI 1609043637
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.6% of the total across 166 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 29 manufacturers reported payments, led by Abbott at 43.1% of the total. Reporting peaked in 2023 at $1,978 and has fallen 77.7% since, to $441 in 2025. That places this record below the midpoint for advanced heart failure and transplant cardiology clinicians in TX, where the typical reported total is $11,093.
Across 166 payments — averaging $36.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$3K
- Abiomed$1K
- Actelion Pharmaceuticals US, Inc.$305
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$280
- Boston Scientific$228
- Impulse Dynamics (USA) Inc.$192
- plus $1K from 23 others
What the payments were for
- Travel & lodging$5138%
- Food & beverage$5,56492%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 55 | $2,620 |
| Abiomed | 7 | $1,146 |
| Actelion Pharmaceuticals US, Inc. | 14 | $305 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 17 | $280 |
| Boston Scientific | 8 | $228 |
| Impulse Dynamics (USA) Inc. | 5 | $192 |
| Medtronic(2 entities) | 6 | $170 |
| Amgen | 8 | $166 |
| Pfizer | 9 | $148 |
| Bridgebio Pharma, Inc. | 1 | $124 |
| Baxter Healthcare | 3 | $106 |
| Johnson & Johnson(2 entities) | 5 | $104 |
| Novartis | 6 | $102 |
| Tactile Systems Technology Inc | 4 | $72 |
| Alnylam Pharmaceuticals Inc. | 2 | $36 |
| Merck | 1 | $31 |
| E.r. Squibb & Sons, L.L.C. | 2 | $30 |
| Heartflow, Inc. | 2 | $26 |
| Edwards Lifesciences | 1 | $23 |
| Cvrx, Inc. | 1 | $22 |
| Astellas Pharma US Inc | 1 | $22 |
| Bayer | 1 | $22 |
| Boehringer Ingelheim | 1 | $21 |
| Elutia, Inc. | 1 | $18 |
| AbbVie | 1 | $15 |
| Haemonetics Corporation | 1 | $14 |
| GE HealthCare | 1 | $13 |
| Braemar Manufacturing, LLC | 1 | $11 |
| Bardy Diagnostics, Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Impella$1,061
- CARDIOMEMS$870
- Attruby$124
- HeartMate 3 Left Ventricular Assist Device$120
- CardioMEMS HF System$111
How this compares
$6,076 in reported general payments places this provider in the 35th percentile of 75 advanced heart failure and transplant cardiology providers in Texas.
See all advanced heart failure and transplant cardiology providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 31 | $832,388 |
| EntrestoSacubitril/Valsartan | 200 | $230,656 |
| EliquisApixaban | 144 | $138,089 |
| AdempasRiociguat | 12 | $122,692 |
| JardianceEmpagliflozin | 57 | $72,456 |
| FarxigaDapagliflozin Propanediol | 46 | $49,588 |
| XareltoRivaroxaban | 23 | $24,264 |
| OzempicSemaglutide | 14 | $15,867 |
| Sildenafil Citrate | 32 | $11,905 |
| JanuviaSitagliptin Phosphate | 15 | $8,414 |
| Tacrolimus | 32 | $6,114 |
| Mycophenolate Mofetil | 20 | $3,113 |
| Torsemide | 95 | $2,522 |
| Metoprolol Succinate | 167 | $1,866 |
| Atorvastatin Calcium | 161 | $1,673 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis | $148 | $970,477175 claims |
| NovartisEntresto | $102 | $230,656200 claims |
| BayerAdempas | $22 | $122,69212 claims |
| Boehringer IngelheimJardiance | $21 | $72,45657 claims |
| Johnson & JohnsonXarelto | $104 | $24,26423 claims |
| MerckJanuvia | $31 | $8,41415 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 75 advanced heart failure and transplant cardiology providers in Texas.
Other advanced heart failure and transplant cardiology in Baytown
- Robert GottliebDallas$717K
- Albert HicksTemple$613K
- Allen AndersonSan Antonio$413K
- Martin BerkDallas$379K
- Aasim AfzalPlano$336K
- Kunjan BhattAustin$324K
- Barry TrachtenbergHouston$306K
- Shelley HallDallas$254K
- Arvind BhimarajHouston$216K
- Jerome ThomasAustin$182K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.